In recent years, mutant IDH proteins have been proposed as attractive drug targets for acute myeloid leukemia. Investigators from Beth Israel Deaconess Medical Center have developed a new animal model that supports IDH2 as a therapeutic target for this widespread blood cancer.
Fuente : http://www.eurekalert.org/pub_releases/2014-01/bid…
Hacer un comentario